Ocriplasmin

Summary

Ocriplasmin (CHEMBL2095222) is an approved protein (ATC S01XA22); indicated across 8 conditions including eye disorder and retinal disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: S01XA22
• Indications: 8 conditions
• Clinical trials: 20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2095222
Name	Ocriplasmin
Type	Protein
Max phase	4
ATC	S01XA22

Also known as: Jetrea, MICROPLASMIN, Microplasmin (synthetic human), Ocriplasmin, Ocriplasmina, Ocriplasmine, Plasmin, micro- (synthetic human), Recombinant human microplasmin, OCRIPLASMIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye disorder	4	MONDO:0005328	EFO:0003966
retinal disorder	4	MONDO:0005283	HP:0000479
macular holes	3	MONDO:0006843	EFO:1001028
stroke disorder	2	MONDO:0005098	EFO:0000712
macular degeneration	2	MONDO:0003004	EFO:0009606
retinal vein occlusion	1	MONDO:0006951	EFO:1001157
uveitis	1	MONDO:0020283	EFO:1001231

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE2	14
PHASE3	3
PHASE4	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02035748	PHASE4	COMPLETED	Assessment of Patients Treated With JETREA® for Vitreomacular Traction
NCT00798317	PHASE3	COMPLETED	Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
NCT01429441	PHASE3	COMPLETED	Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
NCT01889251	PHASE3	COMPLETED	A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
NCT00123266	PHASE2	TERMINATED	Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion
NCT00123279	PHASE2	COMPLETED	Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
NCT00123292	PHASE2	TERMINATED	Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
NCT00123305	PHASE2	COMPLETED	Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
NCT00412451	PHASE2	COMPLETED	A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
NCT00412958	PHASE2	COMPLETED	A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
NCT00428129	PHASE2	TERMINATED	Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT
NCT00435539	PHASE2	COMPLETED	A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
NCT00913744	PHASE2	COMPLETED	Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
NCT00986362	PHASE2	COMPLETED	Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
NCT00996684	PHASE2	UNKNOWN	Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
NCT01055535	PHASE2	COMPLETED	Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
NCT01159665	PHASE2	COMPLETED	The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
NCT01194674	PHASE1/PHASE2	TERMINATED	Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
NCT02681809	PHASE2	TERMINATED	A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
NCT01287988	Not specified	COMPLETED	Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).